Key result
Single-dose evolocumab reduces LDL-C by up to ~71% with placebo-like safety in healthy men.
Why the study?
Data on evolocumab pharmacokinetics and pharmacodynamics were derived mostly from Caucasian populations, leaving its single-dose profile, safety, and tolerability in healthy Chinese subjects to be characterized.
What are the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of subcutaneous evolocumab (140 mg and 420 mg) compared with placebo in healthy Chinese subjects?
RCT (n=36)
Double-blind
5:1 ratio to receive either evolocumab or placebo in two parallel cohorts
No
What are the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of subcutaneous evolocumab (140 mg and 420 mg) compared with placebo in healthy Chinese subjects?
Answers are grounded in this paper and cite their sources.
Single subcutaneous doses of evolocumab (140 mg and 420 mg) in healthy Chinese subjects demonstrated nonlinear pharmacokinetics, up to 71% LDL-C reduction, and a placebo-like safety profile consistent with Caucasian populations, supporting its use without ethnic dose adjustment.
Purpose: Evolocumab is a human monoclonal antibody that reduces circulating low-density lipoprotein cholesterol (LDL-C) by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Data on evolocumab pharmacokinetics and pharmacodynamics are derived mostly from Caucasian populations. The objectives of this study were to characterize the single-dose pharmacokinetic and pharmacodynamic parameters, safety, and tolerability of evolocumab in healthy Chinese subjects. Subjects and methods: This was a phase 1, randomized, double-blind, placebo-controlled study (CTR20150465). Two parallel cohorts were randomized 5:1 to receive single subcutaneous injections of either evolocumab (140 mg or 420 mg) or placebo. Pharmacokinetics, pharmacodynamics, and safety were evaluated through day 85. The primary endpoints were maximum concentration (C max ) and area under the drug concentration–time curve from time 0 to time of last quantifiable concentration (AUC last ). Results: Thirty-six men (median age 26) were enrolled to receive evolocumab 140 mg (n=15), evolocumab 420 mg (n=15), or placebo (n=6). After 140 mg and 420 mg evolocumab, mean (SD) C max was 13.8 (3.6 μg/mL and 67.6 (15.2) μg/mL, respectively, and mean (SD) AUC last was 166 (55) day·μg/mL and 1110 (274) day·μg/mL, respectively. LDL-C declined reversibly, with reductions of 70% at 140 mg and 71% at 420 mg. Maximum effects on LDL-C and PCSK9 levels were reached by day 15 and 24 hrs, respectively, at 140 mg, and by day 22 and 4 hrs, respectively, at 420 mg. No serious adverse events occurred and the overall incidence of treatment-emergent adverse events was similar for evolocumab and placebo: 26.7% (140 mg) and 33.3% (placebo); 66.7% (420 mg) and 66.7% (placebo). Conclusion: In this population of healthy Chinese subjects, single 140 mg and 420 mg doses of evolocumab exhibited nonlinear kinetics and more than dose-proportional increases in exposure, were associated with up to 71% reduction in LDL-C, and demonstrated a safety profile similar to placebo.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted an RCT in Healthy Chinese subjects (pharmacokinetic/pharmacodynamic evaluation for dyslipidemia/LDL-C lowering) (n=36). Evolocumab vs. Placebo was evaluated on Maximum concentration (Cmax) and area under the drug concentration-time curve from time 0 to time of last quantifiable concentration (AUClast). Single and evolocumab doses in healthy Chinese men achieved mean Cmax of 13.8 and /mL, reducing LDL-C by up to 71% with placebo-like safety.
Synapse has enriched 10 related papers. Consider them for comparative context: